Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share Dump

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 28, 2021 10:57am

175 Views

Post# 32409147

RE:Share Dump

Forestview wrote: I'm wondering if this share dump is people selling in order to buy GME, AMC, NOK, BB, etc. The mentality being they can make a quick buck and come back to ATE. Again, it's dropping on no news. It's one thing if they released news that was negative. This is just extraneous impacts.

Can't wait to see who's still standing when the music stops for those companies. Guessing the shorters will win ... as they'll reposition their shorts and take advantage of the massive drop that's coming.

<< Previous

Bullboard Posts

Next >>

The top 5 Canadian small-cap AI stocks